Recent Updates
Recently added Catalysts
HSCS Positive Sentiment Score: 75/100

HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase

Key Takeaway: HeartSciences, an AI-based medical technology company, announced participation in the Gilmartin Group Emerging Growth Showcase on September 21, 2023. CEO Andrew Simpson will engage in a fireside chat discussing HeartSciences' innovations, particularly its MyoVista® wavECG™ product aimed at improving ECG utility in clinical settings. The company is focused on transforming the accuracy of ECGs to aid in early heart disease detection. Investors and interested parties can access the live webcast through HeartSciences' website.

Market Sentiment Analysis

POSITIVE FACTORS

  • HeartSciences is showcasing its innovative AI-based medical technology.
  • Participation in the Emerging Growth Showcase highlights company visibility.
  • The MyoVista® wavECG™ aims to significantly enhance cardiac testing.

Full Press Release Details

Southlake, TX, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson, will participate in a fireside chat at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 11:30 am ET.
To access the live webcast, please visit the Investors page of the HeartSciences website. To ask a question, please feel free to send your questions ahead of time to investorrelations@heartsciences.com. The webcast will be available for replay on HeartSciences’ investor relations website at https://ir.heartsciences.com/.
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical usefulness. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG™, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista® Device and consumables for each test, is expected to be "razor-razorblade" as the electrodes used with the MyoVista® are proprietary to HeartSciences, and new electrodes are required for every test performed.
For more information, please visit: https://www.heartsciences.com. Twitter: @HeartSciences
+1-737-414-9213 (US)

Tags

Heart Test Laboratories
Emerging Growth Showcase

Frequently Asked Questions

What is HeartSciences' main focus?

HeartSciences focuses on AI-based medical technology to enhance ECGs for better heart disease detection.

When is the Gilmartin Group event featuring HeartSciences?

The event is on September 21, 2023, at 11:30 am ET.

What is the MyoVista® device?

The MyoVista® is a 12-lead ECG designed to diagnose cardiac dysfunction using AI.

How can I access the HeartSciences webcast?

You can access the live webcast on the Investors page of HeartSciences' website.

What is the business model of HeartSciences?

HeartSciences uses a 'razor-razorblade' model, requiring proprietary electrodes for each test.

Last updated: Sep 12, 2023